Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 13Gliosarcoma 11Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 7Adenocarcinoma of Lung 7Pancreatic Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Lung Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Glioma 4Adenocarcinoma, Bronchiolo-Alveolar 4Vaginal Neoplasms 3Oropharyngeal Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hemoptysis × Radiation × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡